CF
YMAB

CNA Financial’s Y-mAbs Therapeutics YMAB Stock Holding History

CNA Financial’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-16,720
Closed -$241K – 164
2022
Q3 		$241K Sell
16,720
-7,190
-30% -$119K 0.09% 154
2022
Q2 		$362K Sell
23,910
-1,540
-6% -$18K 0.13% 149
2022
Q1 		$302K Buy
25,450
+7,220
+40% +$74.1K 0.09% 173
2021
Q4 		$296K Buy
18,230
+4,470
+32% +$95.5K 0.08% 181
2021
Q3 		$393K Buy
13,760
+470
+4% +$14.8K 0.11% 176
2021
Q2 		$449K Buy
13,290
+910
+7% +$29.2K 0.13% 171
2021
Q1 		$374K Buy
12,380
+1,600
+15% +$65.6K 0.11% 177
2020
Q4 		$534K Buy
10,780
+890
+9% +$41.2K 0.17% 151
2020
Q3 		$380K Buy
9,890
+600
+6% +$23.9K 0.14% 155
2020
Q2 		$401K Buy
+9,290
New +$351K 0.16% 147

Other funds holding YMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CNA Financial's YMAB Position: Q4 2022 in Review

CNA Financial sold out of Y-mAbs Therapeutics (YMAB) in Q4 2022, closing a stake of 16,720 shares — an estimated $241K sold.

CNA Financial first reported a position in YMAB in Q2 2020 and held it in 10 quarters. The position peaked at $534K in Q4 2020. 91 funds tracked by Wall St. Rank hold YMAB as of Q4 2022.

  • CNA Financial reported no remaining Y-mAbs Therapeutics position as of Q4 2022 after selling out during the quarter.
  • CNA Financial sold 16,720 Y-mAbs Therapeutics shares in Q4 2022, an estimated $241K.
  • CNA Financial first reported a position in Y-mAbs Therapeutics in Q2 2020 and held it in 10 quarters.
  • CNA Financial's Y-mAbs Therapeutics position peaked at $534K in Q4 2020.
  • 91 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2022.

Based on CNA Financial's 13F filing for Q4 2022, filed 10 Feb 2023.